Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Achilles Therapeutics Plc (NQ: ACHL )

0.7744 UNCHANGED
Streaming Delayed Price Updated: 3:59 PM EDT, Apr 25, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 0
Open 0.7744
Bid (Size) 0.7700 (6)
Ask (Size) 0.8488 (2)
Prev. Close 0.7744
Today's Range 0.7744 - 0.7744
52wk Range 0.7400 - 1.760
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Dow Dips Over 200 Points; RPM International Shares Fall After Q3 Results
U.S. stocks turned lower toward the end of trading, with the Dow Jones index falling more than 200 points on Thursday. The Dow traded down 0.59% to 38,894.58 while the NASDAQ fell 0.10% to 16,261.88.... 
Via Benzinga
Topics Stocks
Exposures US Equities
Why STAAR Surgical Shares Are Trading Higher By Around 13%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
Shares of STAAR Surgical Company (NASDAQ: STAA) rose sharply during Thursday’s session after the company issued strong preliminary first-quarter net sales guidance. STAAR Surgical shares jumped 13.3%... 
Via Benzinga

Performance

YTD
-11.19%
-11.19%
1 Month
-37.55%
-37.55%
3 Month
-19.42%
-19.42%
6 Month
-10.47%
-10.47%
1 Year
-5.56%
-5.56%

More News

Read More
12 Health Care Stocks Moving In Thursday's Intraday Session
Via Benzinga
Achilles Therapeutics: Q1 Earnings Insights
Via Benzinga
Nasdaq Surges 1%; ConAgra Brands Posts Upbeat Earnings
Via Benzinga
Topics Stocks
Exposures US Equities
ACHL Stock Earnings: Achilles Therapeutics Misses EPS for Q4 2023
Via InvestorPlace
12 Health Care Stocks Moving In Thursday's Pre-Market Session
Via Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday
Via InvestorPlace
Achilles Therapeutics Reports Fourth Quarter and Year-End 2023 Financial Results and Recent Business Highlights
From Achilles Therapeutics PLC
Via GlobeNewswire
Achilles Therapeutics Provides Interim Phase I/IIa Update on Clonal Neoantigen Reactive T Cells in Advanced NSCLC and Melanoma Including First Patients Dosed with Enhanced Host Conditioning
From Achilles Therapeutics PLC
Via GlobeNewswire
Achilles Therapeutics to Present at the 10th Annual Immuno-Oncology 360 Conference
From Achilles Therapeutics PLC
Via GlobeNewswire
Achilles Therapeutics Announces Publication of Nature Cancer ‘Comment’ on Strategy for Improved Neoantigen Immunogenicity Prediction
From Achilles Therapeutics PLC
Via GlobeNewswire
Achilles Therapeutics Reports Third Quarter 2023 Financial Results and Recent Highlights
From Achilles Therapeutics PLC
Via GlobeNewswire
10 Biotech Stocks Below Cash Value with Key Catalysts on the Horizon: An Analysis
Via ACCESSWIRE
Pathways to Progress: How Orphan Drug Designation Sparks Biotech Transformation
Via Investor Brand Network
Exposures Product Safety
Pathways to Progress: How Orphan Drug Designation Sparks Biotech Transformation
Via FinancialNewsMedia
Exposures Product Safety
12 Health Care Stocks Moving In Thursday's After-Market Session
Via Benzinga
Achilles Therapeutics Reports Second Quarter 2023 Financial Results and Recent Business Highlights
From Achilles Therapeutics PLC
Via GlobeNewswire
Achilles Therapeutics to Present at Upcoming Conferences
From Achilles Therapeutics PLC
Via GlobeNewswire
3 Stocks With 1,000% Upside Potential
Via InvestorPlace
Achilles Therapeutics Reports First Quarter 2023 Financial Results and Recent Business Highlights
From Achilles Therapeutics PLC
Via GlobeNewswire
Achilles Therapeutics’ New Immunogenicity Prediction Application of its AI-Powered PELEUS™ Platform Uniquely Identifies the Most Potent T Cell Antigens
From Achilles Therapeutics PLC
Via GlobeNewswire
Achilles Therapeutics Receives Nasdaq Deficiency Notice Regarding Minimum Bid Price Requirement
From Achilles Therapeutics PLC
Via GlobeNewswire
Achilles Therapeutics Announces Grant of US Patent Covering the Treatment of Patients with an Immunotherapy Targeting Neoantigens Based on Tumor HLA Status
From Achilles Therapeutics PLC
Via GlobeNewswire
Achilles Therapeutics to Present at Chardan’s 7th Annual Genetic Medicines and Cell Therapy Manufacturing Summit
From Achilles Therapeutics PLC
Via GlobeNewswire
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.